These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16922650)

  • 1. The use of accelerator mass spectrometry to obtain early human ADME/PK data.
    Lappin G; Garner RC
    Expert Opin Drug Metab Toxicol; 2005 Jun; 1(1):23-31. PubMed ID: 16922650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
    Garner RC
    Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New ultrasensitive detection technologies and techniques for use in microdosing studies.
    Lappin G; Wagner CC; Langer O; van de Merbel N
    Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdosing for early biokinetic studies in humans.
    Stenström K; Sydoff M; Mattsson S
    Radiat Prot Dosimetry; 2010; 139(1-3):348-52. PubMed ID: 20167793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mini-Review: Comprehensive Drug Disposition Knowledge Generated in the Modern Human Radiolabeled ADME Study.
    Spracklin DK; Chen D; Bergman AJ; Callegari E; Obach RS
    CPT Pharmacometrics Syst Pharmacol; 2020 Aug; 9(8):428-434. PubMed ID: 32562380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.
    Barker J; Garner RC
    Rapid Commun Mass Spectrom; 1999; 13(4):285-93. PubMed ID: 10097404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement.
    Garner RC
    Curr Drug Metab; 2000 Sep; 1(2):205-13. PubMed ID: 11465084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range.
    Sandhu P; Vogel JS; Rose MJ; Ubick EA; Brunner JE; Wallace MA; Adelsberger JK; Baker MP; Henderson PT; Pearson PG; Baillie TA
    Drug Metab Dispos; 2004 Nov; 32(11):1254-9. PubMed ID: 15286054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdosing: a valuable tool for accelerating drug development and the role of bioanalytical methods in meeting the challenge.
    Ings RM
    Bioanalysis; 2009 Oct; 1(7):1293-305. PubMed ID: 21083052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of mass spectrometry for in-vitro ADME assays.
    Chu I; Nomeir AA
    Curr Drug Metab; 2006 Jun; 7(5):467-77. PubMed ID: 16787156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
    Wagner CC; Langer O
    Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of early human data on clinical development: there is time to win.
    Swart P; Lozac'h F; Simon M; van Duijn E; Vaes WH
    Drug Discov Today; 2016 Jun; 21(6):873-9. PubMed ID: 27046542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of liquid chromatography-accelerator mass spectrometry (LC-AMS) to evaluate the metabolic profiles of a drug candidate in human urine and plasma.
    Prakash C; Shaffer CL; Tremaine LM; Liberman RG; Skipper PL; Flarakos J; Tannenbaum SR
    Drug Metab Lett; 2007 Aug; 1(3):226-31. PubMed ID: 19356047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The best model for humans is human -- how to accelerate early drug development safely.
    Seymour M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():61-5. PubMed ID: 19807205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics.
    Lappin G; Stevens L
    Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1021-33. PubMed ID: 18680438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of accelerator MS in pediatric drug evaluation.
    Vuong LT; Blood AB; Vogel JS; Anderson ME; Goldstein B
    Bioanalysis; 2012 Aug; 4(15):1871-82. PubMed ID: 22943618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.